Vericel Corporation Details

About Vericel Founded in 1989, Vericel (formerly Aastrom Biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe disease...
About Vericel Founded in 1989, Vericel (formerly Aastrom Biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two cell therapy products in the United States, Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM). To fulfill Vericel's mission of helping people with severe diseases and conditions realize the promise of patient-specific cell therapy, we hold fast to our values, always using rigorous scientific methods to test hypotheses and evaluate our products' potential. Personal integrity and accountability to our stakeholders are the foundations of our work, and we seek to practice transparency and openness in our dealings with each other, our patients, and our investors. ----- Vericel (formerly Aastrom Biosciences) is developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. Aastrom markets two autologous cell therapy products in the United States for the treatment of cartilage repair and skin replacement. Aastrom is also developing MACI™, a third-generation autologous chondrocyte implantation product for the treatment of focal chondral cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.
Website
Employees
Headquarter
(617) 588-5555
Location
Cambridge, Massachusetts
Revenue
$7M

Employees

Senior Clinical Account Specialist
Medical Consultant
Senior Cell Therapy Specialist
CTS- Cell Therapy Specialist
Clinical Research Liaison

Prospect on LinkedIn

Find verified emails and direct dial phone numbers of contacts on LinkedIn, and sync them with your CRM instantly
Download ExtensionRepresents linkedin prospector
Browse Apollo's Directories

Find Verified Emails in Seconds

Use Apollo to easily get in touch with anyone in the world